Citation Impact
Citing Papers
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
2010 StandoutNobel
Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer
2006
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
2008 StandoutNobel
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
2009 Standout
Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors
2009
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
2009 StandoutNobel
Dendritic cells in cancer immunology and immunotherapy
2019 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Cellular Vaccine Approaches
2010
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study1
2006
Immunosuppressive networks in the tumour environment and their therapeutic relevance
2005 Standout
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
Active immunization against cancer with dendritic cells: The near future
2001 StandoutNobel
Adenovirus Transduction and Culture Conditions Affect the Immunogenicity of Murine Dendritic Cells
2005
The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease
2000
Immunology and immunotherapy approaches for prostate cancer
2007
Cancer epidemiology in the last century and the next decade
2001 Nature
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen
2005
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Cancer immunotherapy via dendritic cells
2012 Standout
The use of dendritic cells in cancer immunotherapy
2003 StandoutNobel
A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma
1997
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Cancer immunotherapy: moving beyond current vaccines
2004 Standout
Gene methylation and early detection of genitourinary cancer: the road ahead
2007
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Exploiting dendritic cells to improve vaccine efficacy
2002 StandoutNobel
Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer
2009
Risks of breast and testicular cancers in young adult twins in England and Wales: evidence on prenatal and genetic aetiology
1997
Immunotherapy for prostate cancer
2006
CD54 is a surrogate marker of antigen presenting cell activation
2008
Inflammation and cancer: back to Virchow?
2001 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis
2011
Actual Causes of Death in the United States, 2000
2004 Standout
Therapeutic vaccines for cancer: an overview of clinical trials
2014
Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer
2012 StandoutNobel
The First 1000 Dendritic Cell Vaccinees
2003
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
2015 Standout
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC☆
1999 Standout
Environmental and Heritable Factors in the Causation of Cancer — Analyses of Cohorts of Twins from Sweden, Denmark, and Finland
2000 Standout
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
2006
Immunotherapy for prostate cancer
2007
Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma
2002
Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults
2003 Standout
Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells.
2002
Exploiting dendritic cells to improve vaccine efficacy
2002 StandoutNobel
Exploiting dendritic cells to improve vaccine efficacy
2002 StandoutNobel
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
2008 StandoutNobel
Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
2013
Current concepts in the diagnosis and management of cytokine release syndrome
2014 Standout
Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients
2006 StandoutNobel
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
The B7 Family and Cancer Therapy: Costimulation and Coinhibition
2007 StandoutNobel
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
2008 StandoutNobel
Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy
2008 StandoutNobel
Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer
2006
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
2011
Gold Nanoparticles in Chemical and Biological Sensing
2012 Standout
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
2008 Standout
Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance
2002 StandoutNobel
Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer
2011
URINARY TRACT CANCER AND HEREDITARY NONPOLYPOSIS COLORECTAL CANCER: RISKS AND SCREENING OPTIONS
1998
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
2007 StandoutNobel
Dendritic Cells Charged with Apoptotic Tumor Cells Induce Long-Lived Protective CD4+ and CD8+ T Cell Immunity against B16 Melanoma
2003 StandoutNobel
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
1999 Standout
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
2007 Standout
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
2007 StandoutNobel
Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients
2005 StandoutNobel
Rational approaches to human cancer immunotherapy
2003
Works of Patrick Burch being referenced
Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen‐independent prostate cancer: A phase 2 trial
2004
Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma
1998
Principles and Practice of Genitourinary Oncology
1998
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
2000
Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.
2000